Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Lynx1 Capital Management
Deal Size : $40.0 million
Deal Type : Series C Financing
Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
Details : The Company plans to use proceeds to complete an international Phase 2 double-blind, randomized, placebo-controlled clinical trial of its investigational drug Valproic Acid (CT-010) for the treatment of uncontrolled seizures in patients with medically re...
Product Name : CT-010
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Lynx1 Capital Management
Deal Size : $40.0 million
Deal Type : Series C Financing
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2b, randomized, placebo-controlled, double-blind study is designed to expand on positive results of the ongoing Phase 1b/2a study assessing the safety and efficacy of intracerebroventricular administration of sodium valproate.
Product Name : CT-010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : RA Capital Management
Deal Size : $35.0 million
Deal Type : Series B Financing
Cerebral Therapeutics Completes $35 Million Series B Financing
Details : The funding will help the company to initiate Phase 2b clinical trial for the treatment of medically refractory epilepsy in 2020.
Product Name : CT-010
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : RA Capital Management
Deal Size : $35.0 million
Deal Type : Series B Financing